$TARA

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

NEW YORK, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. ( Nasdaq: TARA ) , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m.

Original reporting
GlobeNewswire · Protara Therapeutics
Published Nov 18, 2025, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 19, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 — source image
Decision brief

The 30-second read

$TARANeutralMed
01

Why it matters

Positive interim data could validate the company's clinical approach, potentially boosting stock value.

02

Market read

The upcoming data review is a significant event for investors and could influence stock performance.

03

What to watch

Market-wide biotech sector downturns or macroeconomic factors could overshadow company-specific news.

Timing: Within 1-2 weeks around the data release date

Background

Protara Therapeutics is developing therapies for cancer and rare diseases, with recent focus on pediatric lymphatic malformations.

Company-level read

Ticker impact

$TARANeutralMedium confidence
Context

High relevance due to recent news and sentiment

Expected impact

Potential short-term increase in stock price upon positive data release; risk of decline if data is disappointing.

Evidence & confidence

The news pertains to upcoming data release, which can influence investor sentiment, but actual results are unknown.

Market effects

Potential positive impact on biotech and life sciences sector

Limited regional impact, primarily US-focused

Moderate, as biotech sector is globally interconnected

Counterpoint

The upcoming data may be disappointing, leading to a decline in stock price; avoid overreacting.

Key entities

  • Protara Therapeutics

    A clinical-stage biotech company specializing in cancer and rare diseases.

  • TARA-002

    Therapeutic candidate under Phase 2 trial for pediatric lymphatic malformations.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.